文献速递淋巴瘤

格菲妥单抗联合维泊妥珠单抗治疗CAR-T失败后R/R DLBCL的疗效与安全性

[The efficacy and safety of glofitamab combined with polatuzumab vedotin in the treatment of 9 cases of relapsed/refractory diffuse large B-cell lymphoma after failing CAR-T cell therapy].
PubMed 文献 · Zhonghua Xue Ye Xue Za Zhi · 2026-01-01

该回顾性研究纳入9例CAR-T治疗失败的复发/难治弥漫大B细胞淋巴瘤患者,接受格菲妥单抗联合维泊妥珠单抗治疗。6周期后总缓解率77.8%,完全缓解率55.6%;中位随访12个月,1年无进展生存率71.1%,总生存率76.2%。所有患者发生细胞因子释放综合征,多为1-2级,安全性可控。

要点

  • CAR-T失败后R/R DLBCL接受格菲妥单抗联合维泊妥珠单抗,完全缓解率达55.6%。
  • 1年无进展生存率71.1%,1年总生存率76.2%。

核心结论

  • 格菲妥单抗联合维泊妥珠单抗在CAR-T治疗失败的R/R DLBCL中显示出初步疗效且安全性可控。

研究设计与样本

  • 回顾性分析2024年3月至2025年4月天津市第一中心医院血液科9例CAR-T治疗失败后接受格菲妥单抗联合维泊妥珠单抗治疗的R/R DLBCL患者临床资料。

主要发现

  • 6个周期后总缓解率为77.8%,完全缓解率为55.6%。
  • 中位随访12(5~18)个月,1年无进展生存率为71.1%(95% CI:56.3%~86.1%)。
  • 1年总生存率为76.2%(95% CI:64.0%~94.2%)。
  • 9例患者均发生细胞因子释放综合征,其中7例为1~2级、2例为3级。
  • 1例发生1级免疫效应细胞相关神经毒性综合征。

临床怎么用

  • 对于CAR-T治疗失败的R/R DLBCL患者,可考虑格菲妥单抗联合维泊妥珠单抗作为治疗选择。
  • 治疗期间需重点监测细胞因子释放综合征和免疫效应细胞相关神经毒性综合征。

局限性

  • 本研究为单中心回顾性分析,样本量仅9例。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

To evaluate the efficacy and safety of glofitamab combined with polatuzumab vedotin in the treatment of relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) after failure of chimeric antigen receptor T (CAR-T) cell therapy. Nine patients with R/R DLBCL who failed CAR-T therapy and received glofitamab combined with polatuzumab vedotin treatment at the Hematology Department of Tianjin First Central Hospital from March 2024 to April 2025 were selected for retrospective analysis of their clinical data. The overall response rate was 77.8%, and the complete response rate was 55.6% following six cycles of treatment. The median follow-up period was 12 (5-18) months. The 1-year progression-free survival rate and overall survival rate were 71.1% (95% CI: 56.3%-86.1%) and 76.2% (95% CI: 64.0%-94.2%), respectively. All 9 patients experienced cytokine release syndrome, with 7 cases at grade 1-2 and 2 cases at grade 3. One patient had grade 1 immune effector cell-associated neurotoxicity syndrome. Glofitamab combined with polatuzumab vedotin shows preliminary efficacy and a manageable safety in patients with R/R DLBCL after CAR-T cell therapy failure. 为探讨格菲妥单抗联合维泊妥珠单抗治疗嵌合抗原受体T(CAR-T)细胞治疗失败的复发/难治弥漫大B细胞淋巴瘤(R/R DLBCL)疗效及安全性,纳入2024年3月至2025年4月期间在天津市第一中心医院血液科接受格菲妥单抗联合维泊妥珠单抗治疗的CAR-T细胞治疗失败的9例R/R DLBCL患者,对其临床资料进行回顾性分析。6个周期后患者总缓解率为77.8%,完全缓解率为55.6%。中位随访12(5~18)个月,1年无进展生存率和总生存率分别为71.1%(95% CI:56.3%~86.1%)和76.2%(95% CI:64.0%~94.2%)。9例患者均发生细胞因子释放综合征,其中7例为1~2级、2例为3级。1例发生1级免疫效应细胞相关神经毒性综合征。格菲妥单抗联合维泊妥珠单抗治疗CAR-T细胞治疗失败的R/R DLBCL显示出初步疗效且安全性可控。.

来源:Zhonghua Xue Ye Xue Za Zhi,查看原文。版权归原作者所有。

引用

  1. Zhang H, He XY, Xiao X, et al. [The efficacy and safety of glofitamab combined with polatuzumab vedotin in the treatment of 9 cases of relapsed/refractory diffuse large B-cell lymphoma after failing CAR-T cell therapy]. Zhonghua Xue Ye Xue Za Zhi. 2026. PMID: 42706179. doi:10.3760/cma.j.cn121090-20251219-00604

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。